0000874015-19-000079.txt : 20190626
0000874015-19-000079.hdr.sgml : 20190626
20190626185219
ACCESSION NUMBER: 0000874015-19-000079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190624
FILED AS OF DATE: 20190626
DATE AS OF CHANGE: 20190626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BERTHELSEN SPENCER R
CENTRAL INDEX KEY: 0001181548
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 19922713
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-06-24
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001181548
BERTHELSEN SPENCER R
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD
CA
92010
1
0
0
0
Common Stock
2019-06-24
2019-06-24
4
M
0
5310
16.32
A
99404
D
Common Stock
2019-06-24
2019-06-24
4
S
0
5310
63.3661
D
94094
D
Common Stock
2019-06-24
2019-06-24
4
M
0
9690
16.32
A
103784
D
Common Stock
2019-06-24
2019-06-24
4
S
0
9690
63.843
D
94094
D
Common Stock
70
I
By daughter
Director Stock Option (right to buy)
16.32
2019-06-24
2019-06-24
4
M
0
15000
0
D
2013-07-01
2019-06-30
Common Stock
15000
0
D
Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.68 to $63.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.16, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/Patrick R. O'Neil, attorney-in-fact
2019-06-26